Jonathan P Belk

US Patent:

7700739, Apr 20, 2010

Filed:

Jun 29, 2006

Appl. No.:

11/478096

Inventors:

Susan E. Lacy - Shrewsbury MA,
Emma Fung - Shrewsbury MA,
Jonathan P. Belk - Sterling MA,
Richard W. Dixon - Jefferson MA,
Michael Roguska - Ashland MA,
Paul R. Hinton - Sunnyvale CA,
Shankar Kumar - Pleasanton CA,

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 16/00

US Classification:

5303871, 4241301

Abstract:

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

US Patent:

7915388, Mar 29, 2011

Filed:

Sep 7, 2007

Appl. No.:

11/899819

Inventors:

Chengbin Wu - Shrewsbury MA,
Richard W. Dixon - Jefferson MA,
Jonathan P. Belk - Sterling MA,
Maria A. Argiriadi - Wayland MA,
Hua Ying - Holden MA,
Carolyn A. Cuff - Grafton MA,
Terry L. Melim - Derry NH,
Shankar Kumar - Pleasanton CA,
Paul R. Hinton - Sunnyvale CA,
Yan Chen - Fremont CA,

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12P 21/08

US Classification:

5303879, 4241331

Abstract:

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e. g. , in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

US Patent:

8604177, Dec 10, 2013

Filed:

Mar 8, 2011

Appl. No.:

13/043293

Inventors:

Chengbin Wu - Shrewsbury MA,
Richard W. Dixon - Jefferson MA,
Jonathan P. Belk - Sterling MA,
Maria A. Argiriadi - Wayland MA,
Hua Ying - Holden MA,
Carolyn A. Cuff - Grafton MA,
Terry L. Melim - Derry NH,
Shankar Kumar - Pleasanton CA,
Paul R. Hinton - Sunnyvale CA,
Yan Chen - Fremont CA,

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

C07H 21/04

US Classification:

536 2353, 435325

Abstract:

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e. g. , in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

US Patent:

8629257, Jan 14, 2014

Filed:

Apr 19, 2010

Appl. No.:

12/763048

Inventors:

Susan E. Lacy - Shrewsbury MA,
Emma Fung - Shrewsbury MA,
Jonathan P. Belk - Sterling MA,
Richard W. Dixon - Jefferson MA,
Michael Roguska - Ashland MA,
Paul R. Hinton - Sunnyvale CA,
Shankar Kumar - Pleasanton CA,

Assignee:

Abbvie Inc. - North Chicago IL

International Classification:

C07H 21/04

US Classification:

536 2353, 5303871, 435326

Abstract:

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

US Patent:

2005022, Oct 13, 2005

Filed:

Apr 12, 2004

Appl. No.:

10/822306

Inventors:

Edward Reilly - Libertyville IL,
Susan Lacy - Shrewsbury MA,
Emma Fung - Shrewsbury MA,
Jonathan Belk - Sterling MA,
Michael Roguska - Ashland MA,

International Classification:

C07K016/28
C12Q001/70
G01N033/53

US Classification:

435007100, 530388220

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.

US Patent:

2006001, Jan 26, 2006

Filed:

Apr 8, 2005

Appl. No.:

11/102424

Inventors:

Edward Reilly - Libertyville IL,
Susan Lacy - Shrewsbury MA,
Emma Fung - Shrewsbury MA,
Jonathan Belk - Sterling MA,
Michael Roguska - Ashland MA,

International Classification:

A61K 39/395
C07K 16/28

US Classification:

424143100, 530388220

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.

US Patent:

2008003, Feb 14, 2008

Filed:

Dec 21, 2006

Appl. No.:

11/614772

Inventors:

Edward Reilly - Libertyville IL,
Susan Lacy - Shrewsbury MA,
Emma Fung - Shrewsbury MA,
Jonathan Belk - Sterling MA,
Michael Roguska - Ashland MA,
Vincent Stoll - Libertyville IL,
Clarissa Jakob - Grayslake IL,

International Classification:

A61K 39/395
A61P 43/00
C07K 16/24
C07K 7/06
G06G 7/60

US Classification:

424139100, 424130100, 530328000, 530388220, 530389100, 703011000

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions. The invention further provides compositions and crystals of an erythropoietin receptor in complex with an anti-erythropoietin receptor antibody. Specifically, the high-resolution structure provides binding sites defined by the structure coordinated determined herein.

US Patent:

2009026, Oct 22, 2009

Filed:

Mar 3, 2009

Appl. No.:

12/380703

Inventors:

Chung-ming Hsieh - Newton MA,
Jonathan P. Belk - Grantham NH,
Jennifer M. Perez - Worcester MA,
Lorenzo Benatuil - Medford MA,

International Classification:

C40B 50/06
C12N 1/19

US Classification:

506 26, 4352542

Abstract:

This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.